Semaglutide: the medication, the brands, and the price landscape
Semaglutide is a once-weekly GLP-1 receptor agonist, FDA-approved as Wegovy (weight management), Ozempic (type 2 diabetes), and in oral form (Rybelsus; the oral Wegovy pill launched January 2026 from $149/mo). Cash prices in 2026: Wegovy $349/mo standard via NovoCare↗ ($199 intro); verified compounded programs $133–$348/mo all-in — the same narrowed 503A lane as tirzepatide.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
How the market prices it
Titration runs 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, and the start-versus-maintenance gap is where semaglutide marketing hides: programs advertising $149 or $169 bill $179–$289 at maintenance, while dose-flat programs (NexLife $165, Mochi $178 all-in) hold one number. With Wegovy at $349 and the pill from $149, the compounded discount is the thinnest it has ever been — the pages that settle it: the ranked market, the market in prose, compounded vs Wegovy, the safety question, sorted.
Averages are for approved products in trials, not predictions or claims about compounded copies; talk to a prescriber.